Abstract 50P
Background
As we enter an aging society, the number of elderly breast cancer patients is increasing. We assessed the prognostic factors of recurrence or metastasis for breast cancer patients over the age of 65 by analyzing the characteristics of tumor and long-term clinical outcomes.
Methods
Data were retrospectively analyzed for 286 breast cancer patients aged 65 years and older who underwent treatment in the Pusan national university hospital and Pusan national university Yangsan hospital from 2008 to 2014. Dividing two groups as the patients with event such as recurrence or metastasis and those who without it, the Cox regression model was used to examine the risk factors of recurrence or metastasis.
Results
Among 286 patients with invasive breast cancer, forty three patients (15.0%) have been found to have recurrence or distant metastasis during median follow-up period of 61 months. The poor prognosis was found in the advanced stage of breast cancer, patients without endocrine therapy and low Allred scores of estrogen receptor.Table: 50P
Variable | Hazard ratio | P-value | 95% CI |
---|---|---|---|
Stage | 1.78 | <0.0001 | (1.39, 2.28) |
Endocrine therapy | 0.04 | 0.0002 | (0.01, 0.23) |
Estrogen receptor | 1.34 | 0.0076 | (1.08, 1.66) |
Conclusions
The advanced stage of breast cancer was poor prognosis in the elderly breast cancer patients. Moreover, endocrine therapy should be performed on elderly breast cancer patients with high Allred score of estrogen receptor because it is good for prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract